Australia is facing fierce competition to secure supply of Moderna’s vaccine for children under six, which received provisional approval from the Therapeutic Goods Administration on Tuesday.
The TGA announced it had provisionally approved Moderna’s COVID-19 vaccine for children aged six months to five years of age.
Loading...
Michael Read is the Financial Review's economics correspondent, reporting from the federal press gallery at Parliament House. He was previously an economist at the Reserve Bank of Australia and at UBS. Connect with Michael on Twitter. Email Michael at michael.read@afr.com
